Drug companies that manufacture ketamine are expected to lead profits in the category, according to an Anesthesia Drug Market study. Ketalar, distributed by JHP Pharmaceuticals, is currently the only branded version of the drug offered on the market.
Ketalar is expected to maintain a high profile in the market over the next five years, according to the study, but could see a drop in sales due to an increasing demand for less expensive generic counterparts.
Related Articles on Anesthesiology:
Two Anesthesiologists Selected to Lead St. Joseph Medical Center Anesthesia Department
Anesthesiologist Receives American Pain Society Award
Anesthesiologist Elected to Massachusetts Medical Society House of Delegates
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
